Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-risk Neuroblastoma (LuDO-N)

3. november 2026 oppdatert av: Jakob Stenman

A Phase II Trial of 177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-risk Neuroblastoma

The LuDO-N Trial is a multi-centre phase II clinical trial on 177Lu-DOTATATE treatment of recurrent or relapsed high-risk neuroblastoma in children. The LuDO-N Trial builds on the experience from the previous LuDO Trial and utilises an intensified dosing schedule to deliver 2 doses over a 2-week period, in order to achieve a maximal effect on the often rapidly progressing disease. This strategy requires a readiness for autologous stem cell transplantation in all patients, but is not anticipated to increase the risk of long-term sequelae, since the cumulative radiation dose remains unchanged. The primary aim of the study is to assess the response to 177Lu-DOTATATE treatment at 1 and 4 months after end of treatment. Secondary aims are to assess survival and treatment-related toxicity. Additional aim are to correlate tumour dosimetry with response, correlate SSTR-2 expression with 68Ga-DOTATATE uptake and to correlate the uptake with the treatment response.

Studieoversikt

Status

Rekruttering

Intervensjon / Behandling

Studietype

Intervensjonell

Registrering (Antatt)

24

Fase

  • Fase 2

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

Studiesteder

    • Copenhagen
      • Copenhagen, Copenhagen, Danmark, DK-2100
        • Rekruttering
        • Rigshospitalet
        • Ta kontakt med:
        • Hovedetterforsker:
          • Jesper S Brok, MD PhD
    • Vilnius County
      • Vilnius, Vilnius County, Litauen, LT-08406
        • Rekruttering
        • Vilnius University Hospital
        • Ta kontakt med:
        • Hovedetterforsker:
          • Jelena Rascon, MD PhD
    • Utrecht
      • Utrecht, Utrecht, Nederland, NL-3584
        • Rekruttering
        • Princess Maxima Center for Pediatric Oncology
        • Ta kontakt med:
        • Hovedetterforsker:
          • Max M van Noesel, MD PhD
    • Oslo
      • Oslo, Oslo, Norge, NO-0372
        • Rekruttering
        • Oslo University Hospital, Rikshospitalet
        • Ta kontakt med:
        • Hovedetterforsker:
          • Kirsten Brunsvig Jarvis, MD
      • Barcelona, Spania
        • Rekruttering
        • Pediatric Cancer Center Barcelona, Sant Joan de Déu Barcelona Children's Hospital
        • Ta kontakt med:
        • Hovedetterforsker:
          • Maite Gorostegui Obanos, MD
      • Glasgow, Storbritannia, G51 4TF
        • Rekruttering
        • GREATER GLASGOW HEALTH BOARD, Royal Hospital for Children
        • Ta kontakt med:
        • Hovedetterforsker:
          • Diana Mcintosh, MD
      • London, Storbritannia, NW1 2PG
        • Rekruttering
        • University College London Hospitals NHS FOUNDATION TRUST
        • Ta kontakt med:
          • Jenny Gains, Consultant in Clinical Oncolog
          • Telefonnummer: +44-203 447 4437
          • E-post: jenny.gains@nhs.net
        • Hovedetterforsker:
          • Jenny Gains, MD
      • London, Storbritannia, SW3 6JJ
        • Rekruttering
        • The Royal Marsden NHS Foundation Trust of Fulham Road
        • Ta kontakt med:
        • Hovedetterforsker:
          • Sucheta Vaidya, MD

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

1 år og eldre (Barn, Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  1. Pathology 1.1. Histologically confirmed diagnosis of neuroblastoma 1.2. Immunohistochemical staining for somatostatin receptors (SSTR) performed from primary tumor tissue when available
  2. Relapsed or primary refractory high-risk neuroblastoma: INSS stage 4 disease or INRGSS stage M disease
  3. Age >18 months at the time of enrolment into this study
  4. Life expectancy of greater than 3 months
  5. Performance Status 5.1. Karnofsky > 50% (for patients > 12 years of age) 5.2. Lansky > 50% (for patients ≤ 12 years of age)
  6. Prior treatment 6.1. Two-week washout from any prior treatment 6.2. Patients must have recovery of hematological toxicity following previous therapy 6.3. Adequate recovery from major surgery prior to receiving study treatment
  7. Diagnostic imaging 7.1. Uptake in the primary tumor or metastatic tumour deposits on 68Ga-DOTATATE PET/CT at least higher than the liver uptake and performed within two months prior to registration 7.2. 123I-mIBG scintigraphy to be performed within two months prior to registration 7.3. CT or MRI of the primary tumor and bulky metastatic sites within two months prior to registration
  8. Laboratory requirements to be performed within 7 days prior to commencing trial treatment 8.1. Hematology: 8.1.1. Hemoglobin, If Hb is <120 g/L then patient will receive a blood transfusion prior to commencing trial treatment 8.1.2. Absolute neutrophil count > 1.0 x 109/L 8.1.3. Absolute Platelets > 50 x 109/L 8.2. Biochemistry: 8.2.1. Bilirubin within 1.5 x ULN 8.2.2. ALT within 2.5 x ULN 8.2.3. AST within 2.5 x ULN 8.2.4. GGT within 5 x ULN 8.2.5. ALP within 5 x ULN 8.2.6. Glomerular filtration rate >50mL/min/1.73m2 assessed by a recognised method, such as inulin, 51Cr-EDTA, 99mTc-DTPA or iohexol clearance and performed within 2 months prior to registration 8.2.7. Urinary catecholamine metabolites measured within 2 months prior to registration
  9. Peripheral blood stem cells (PBSC) 9.1. A minimum of 2 x106 CD34+ cells/kg (optimally 6 x106 CD34+ cells/kg) must be available for each study subject prior to registration
  10. Written informed consent from patient and/or parent(s) or legal guardian(s) in accordance with national regulations, prior to registration or any trial-related screening procedures

Exclusion Criteria:

  1. Not fit enough to undergo proposed study treatment, as assessed by national PI, considering precautions defined in the latest version of the 177Lutetium-DOTATATE SmPC.
  2. Pregnant or lactating patient
  3. Concurrent treatment with any anti-tumor agents
  4. Prior treatment with other radiolabeled somatostatin analogues
  5. Hypersensitivity to any component of the investigational drug 177Lutetium-DOTATATE
  6. Treatment with long-acting somatostatin analogues within 30 days, or with short-acting somatostatin analogues within 24 hours prior the administration of 177Lutetium-DOTATATE
  7. Hydronephrosis in either kidney on baseline MRI or CT; patients can still be eligible for inclusion if urinary tract obstruction can be ruled out by renography

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Intervensjonsmodell: Enkeltgruppeoppdrag
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: 177Lu-DOTATATE

A total of two doses of 177Lu-DOTATATE will be administered intravenously. The minimum time between treatments is 2 weeks.

A total of two doses of 177Lu-DOTATATE will be administered intravenously. A weight-based activity of 400 MBq kg-1 will be used for the first dose. The activity of the second dose will be calculated based on whole body activity scans as well as SPECT/CT scans to determine the absorbed kidney dose. The aim is to administer 177Lu-DOTATATE corresponding to a whole-body dose of 1,2 Gy, with a cumulative whole-body dose of about 2,4 Gy over two courses, and not exceeding a cumulative renal dose of 23 Gy, to avoid renal toxicity. The aim is to deliver two doses of 177Lu-DOTATATE two weeks apart. The minimum time between treatments is 2 weeks. The maximum time between treatments is 4 weeks.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Response by the Revised International Neuroblastoma Response Criteria (INRC) at 1 month after the completion of therapy
Tidsramme: 1 months following end of treatment

Treatment response assessed in accordance with the Revised International Neuroblastoma Response Criteria (INRC)

1 months following end of treatment

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Response based on 68Ga-DOTATOC PET/CT imaging at 1 and 4 months after completion of therapy in measurable target lesions
Tidsramme: 1 and 4 months following end of treatment

Response based on 68Ga-DOTATOC PET/CT imaging after completion of therapy in measurable target lesions

1 and 4 months following end of treatment
Response based on 123I-mIBG SPECT/CT imaging (when available) at 1 and 4 months after completion of therapy in measurable target lesions
Tidsramme: 1 and 4 months following end of treatment

Response based on 123I-mIBG SPECT/CT imaging (when available) after completion of therapy in measurable target lesions

1 and 4 months following end of treatment
Response by the Revised INRC criteria at 4 months after the completion of therapy
Tidsramme: 4 months following end of treatment

Response by the Revised INRC criteria

4 months following end of treatment
Progression-free survival
Tidsramme: Time from registration to progression or death, up to 5 years following end of treatment

Time to progress or death, whichever occurs first

Time from registration to progression or death, up to 5 years following end of treatment
Overall survival - up to 5 years after End of Treatment
Tidsramme: Time from registration to the the date of death, up to 5 years following end of treatment

Overall survival

Time from registration to the the date of death, up to 5 years following end of treatment
Hematological and renal toxicity according to CTCAE 5.0
Tidsramme: From first treatment dose until the date of first documented progression, assessed up to 60 months

Hematological and renal toxicity according to CTCAE 5.0

From first treatment dose until the date of first documented progression, assessed up to 60 months

Andre resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Dosimetry (absorbed dose in Gy) in measurable target lesions and risk organs
Tidsramme: At every administered dose of 177Lu-DOTATATE throughout the trial treatment phase (5 years)

Measured by SPECT/CT

At every administered dose of 177Lu-DOTATATE throughout the trial treatment phase (5 years)
Semi-quantitative analysis of the expression of SSTR-2 on immunohistochemistry in the primary tumor histology
Tidsramme: Throughout the trial treatment phase (5 years)

Semi-quantitative analysis of the expression of SSTR-2 on immunohistochemistry in the primary tumor histology

Throughout the trial treatment phase (5 years)
The uptake on 68Gallium-DOTATOC PET/CT by SUVmax (maximum standardized uptake value) in measurable target lesions
Tidsramme: At end of treatment, and 1 and 4 months after end of treatment.

Measured by SUVmax (maximum standardized uptake value)

At end of treatment, and 1 and 4 months after end of treatment.

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Etterforskere

  • Studiestol: Jakob Stenman, MD PhD, Karolinska University Hospital

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

19. mai 2021

Primær fullføring (Antatt)

31. desember 2032

Studiet fullført (Antatt)

31. desember 2032

Datoer for studieregistrering

Først innsendt

21. mai 2021

Først innsendt som oppfylte QC-kriteriene

25. mai 2021

Først lagt ut (Faktiske)

27. mai 2021

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

9. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

3. november 2026

Sist bekreftet

1. oktober 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere